<< Back to News

System Formulary Update
​Nirsevimab (Beyfortus) 100 mg/mL Restriction Update
December 9, 2025

The following criteria for nirsevimab was updated to the following:

For infants entering their first RSV season (October-March):
No restriction criteria for inpatient use 
Vaccines For Children (VFC) screening required for VFC-eligible sites
For infants entering their second RSV season (October-March):

RESTRICTED to the following:
Must meet >1 of the following high-risk criteria: 
Chronic lung disease
Severe immunocompromise
Cystic fibrosis
Previously received nirsevimab AND subsequently undergone cardiopulmonary bypass during the same RSV season 
American Indian or Alaska Native